RNAscope Assay for Melanoma Diagnosis via Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing melanoma face challenges due to the difficulty in differentiating between malignant melanoma and benign nevi, with existing molecular markers showing limited sensitivity and specificity, particularly in classifying histologically ambiguous lesions, and there is a need for improved diagnostic accuracy to address the high rate of misdiagnosis and its adverse impacts on patient outcomes.
Innovation Solution
A novel RNA in situ hybridization (ISH) technology platform called RNAscope®, which enables the detection of specific gene expression changes in both tumor cells and tumor-associated stroma, is used to develop a multi-gene assay for diagnosing malignant melanoma by determining the expression levels of PHACTR1, SPP1, PRAME, GDF15, and CXCL10 genes, providing enhanced sensitivity and specificity for early-stage melanoma detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional histological criteria and IHC markers are used for melanoma diagnosis, then the diagnostic process is simple and widely applicable, but the diagnostic accuracy is low with high misdiagnosis rates
Solution Approach 1:
The patent transitions from conventional histological parameters to molecular expression parameters by measuring mRNA levels of specific genes (PHACTR1, SPP1, PRAME, GDF15, CXCL10). This parameter change enables precise quantification of gene expression to differentiate melanoma from benign nevi, directly improving diagnostic accuracy while using standardized molecular biology techniques.
Solution Approach 2:
The patent replaces subjective visual histological examination with objective molecular detection using RNA in situ hybridization. This substitution eliminates inter-observer variability and provides quantitative molecular data, transforming the diagnostic approach from mechanical/visual assessment to molecular detection based on gene expression profiles.
2Measurement precision
If existing molecular markers are used to differentiate melanoma from benign nevus, then some molecular differentiation is achieved, but the sensitivity and specificity remain limited particularly for ambiguous lesions
Solution Approach 1:
The patent employs a composite molecular marker panel consisting of five genes (PHACTR1, SPP1, PRAME, GDF15, CXCL10) rather than relying on single markers. This composite approach combines multiple molecular signals to achieve higher differentiation accuracy and reliability, where the combined expression pattern provides more robust classification than individual markers alone.
Solution Approach 2:
The patent uses RNA in situ hybridization to detect and quantify mRNA expression levels of the marker panel, providing feedback on the molecular state of the lesion. This quantitative molecular feedback enables objective classification and reduces diagnostic uncertainty, particularly for histologically ambiguous cases where conventional methods fail.
3Measurement precision
If RNA in situ hybridization is used to detect gene expression at cellular resolution, then diagnostic precision is significantly improved, but the technical complexity and cost increase
Solution Approach 1:
The patent extracts and detects only the specific mRNA transcripts of the five diagnostic genes using targeted in situ hybridization probes. This extraction approach focuses the complex assay on relevant molecular targets, enabling precise gene expression detection at cellular resolution while managing technical complexity through selective target analysis rather than comprehensive genomic profiling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAscope-based assay significantly improves diagnostic accuracy for melanoma, reducing false positives and unnecessary treatments by enabling cellular resolution of gene expression analysis, thereby providing more precise differentiation between melanoma and benign lesions.
Implementation Method 1
A novel RNA in situ hybridization (ISH) technology platform called RNAscope®, which enables the detection of specific gene expression changes
Data Source
Figure 1
Figure 2a~2b
Figure 3A~3F
AI summary
Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.